X

Trial Profile

Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-methylated Glioblastoma: a Randomized Phase II Open Label Multicenter Study

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romiplostim (Primary) ; Lomustine
Indications Chemotherapy-induced damage; Thrombocytopenia
Focus Therapeutic Use
Acronyms RIGOLETTO

Most Recent Events

24 Sep 2023 This trial has been discontinued in Spain.
13 Aug 2023 This trial has been discontinued in Italy (Date of the global end of the trial: 19 Dec 2022).
23 May 2023 Status changed from recruiting to withdrawn prior to enrolment because Amgen withdrew interest in providing further financial support.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com